On June 4, the Food and Drug Administration (FDA) held a meeting of its Psychopharmacologic Drugs Advisory Committee. The FDA maintains 50 independent committees focused on different fields. Although not required to, it convenes these expert panels when facing difficult decisions.1 In this case, the subject was 3,4-methylenedioxymethamphetamine (MDMA), a Schedule I controlled substance, which shows promise for treating posttraumatic stress disorder.